Neumora Therapeutics IncNASDAQ:NMRA
- LAST PRICE9.9400
- TODAY'S CHANGE (%)0.1800 (1.8443%)
- Bid / Lots9.2000/ 9
- Ask / Lots10.2500/ 3
- Open / Previous Close9.8400 / 9.7600
- Day Range
- 52 Week Range
- Volume450,994
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NMRA |
|---|---|---|
| 09:32 ET | 1924 | 9.84 |
| 09:33 ET | 6556 | 9.71 |
| 09:35 ET | 700 | 9.71 |
| 09:37 ET | 2094 | 9.7 |
| 09:39 ET | 1100 | 9.7078 |
| 09:42 ET | 3300 | 9.7 |
| 09:44 ET | 2347 | 9.7 |
| 09:46 ET | 5981 | 9.7 |
| 09:48 ET | 3185 | 9.81 |
| 09:50 ET | 200 | 9.8 |
| 09:51 ET | 100 | 9.825 |
| 09:53 ET | 600 | 9.78 |
| 09:55 ET | 403 | 9.78 |
| 09:57 ET | 500 | 9.77 |
| 10:00 ET | 1200 | 9.795 |
| 10:02 ET | 1424 | 9.84 |
| 10:06 ET | 400 | 9.845 |
| 10:09 ET | 1966 | 9.97 |
| 10:11 ET | 1504 | 9.985 |
| 10:13 ET | 962 | 10 |
| 10:15 ET | 200 | 10 |
| 10:18 ET | 1445 | 9.98 |
| 10:20 ET | 300 | 9.95 |
| 10:22 ET | 6036 | 9.88 |
| 10:24 ET | 1453 | 9.87 |
| 10:26 ET | 1300 | 9.92 |
| 10:27 ET | 100 | 9.92 |
| 10:29 ET | 975 | 9.88 |
| 10:31 ET | 100 | 9.92 |
| 10:33 ET | 596 | 9.91 |
| 10:36 ET | 1217 | 9.92 |
| 10:38 ET | 400 | 9.91 |
| 10:40 ET | 832 | 9.895 |
| 10:42 ET | 500 | 9.94 |
| 10:44 ET | 1523 | 9.95 |
| 10:45 ET | 2536 | 10.005 |
| 10:47 ET | 1119 | 10.06 |
| 10:51 ET | 650 | 10.09 |
| 10:54 ET | 248 | 10.1298 |
| 10:56 ET | 100 | 10.07 |
| 10:58 ET | 365 | 10.1 |
| 11:02 ET | 8086 | 10.085 |
| 11:03 ET | 1170 | 10.07 |
| 11:05 ET | 989 | 10.085 |
| 11:07 ET | 400 | 10.06 |
| 11:09 ET | 6038 | 10.045 |
| 11:12 ET | 187 | 10.03 |
| 11:14 ET | 1618 | 10.05 |
| 11:16 ET | 300 | 10.055 |
| 11:18 ET | 3241 | 10.02 |
| 11:20 ET | 1844 | 10.069 |
| 11:21 ET | 1197 | 10.08 |
| 11:23 ET | 990 | 10.065 |
| 11:25 ET | 1800 | 10.1 |
| 11:27 ET | 1585 | 10.09 |
| 11:30 ET | 200 | 10.12 |
| 11:32 ET | 258 | 10.1164 |
| 11:34 ET | 500 | 10.095 |
| 11:36 ET | 500 | 10.11 |
| 11:38 ET | 400 | 10.11 |
| 11:39 ET | 400 | 10.095 |
| 11:41 ET | 200 | 10.0802 |
| 11:43 ET | 2453 | 10.0964 |
| 11:45 ET | 100 | 10.06 |
| 11:48 ET | 450 | 10.08 |
| 11:50 ET | 704 | 10.07 |
| 11:52 ET | 2469 | 10.1 |
| 11:54 ET | 803 | 10.095 |
| 11:56 ET | 693 | 10.1 |
| 11:57 ET | 400 | 10.11 |
| 11:59 ET | 1365 | 10.08 |
| 12:01 ET | 3136 | 10.08 |
| 12:03 ET | 1400 | 10.08 |
| 12:06 ET | 1684 | 10.06 |
| 12:08 ET | 500 | 10.06 |
| 12:12 ET | 1358 | 10.03 |
| 12:15 ET | 100 | 9.9872 |
| 12:17 ET | 505 | 9.97 |
| 12:19 ET | 100 | 9.97 |
| 12:21 ET | 1163 | 10 |
| 12:24 ET | 200 | 10.01 |
| 12:26 ET | 1247 | 9.995 |
| 12:30 ET | 403 | 10.01 |
| 12:32 ET | 300 | 10.02 |
| 12:33 ET | 100 | 10.01 |
| 12:35 ET | 2390 | 10.04 |
| 12:37 ET | 5399 | 10 |
| 12:39 ET | 7759 | 10 |
| 12:42 ET | 1782 | 10.03 |
| 12:44 ET | 400 | 10.01 |
| 12:46 ET | 1495 | 10.03 |
| 12:48 ET | 3906 | 10.05 |
| 12:50 ET | 2102 | 10.04 |
| 12:51 ET | 11801 | 9.955 |
| 12:53 ET | 4429 | 10 |
| 12:55 ET | 4838 | 9.96 |
| 12:57 ET | 13975 | 9.96 |
| 01:00 ET | 142020 | 9.94 |
Nov 22, 2024
DJ Neumora Therapeutics Price Target Maintained With a $29.00/Share by RBC Capital, from 12:07PM ET on Friday Nov 22, 2024 by Dow Jones
12:07PM ET on Friday Nov 22, 2024 by Dow Jones
Nov 13, 2024
DJ Neumora Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 11:59AM ET on Wednesday Nov 13, 2024 by Dow Jones
11:59AM ET on Wednesday Nov 13, 2024 by Dow JonesDJ Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham, from 5:20AM ET on Wednesday Nov 13, 2024 by Dow Jones
5:20AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Press Release: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow JonesNeumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neumora Therapeutics Inc | 1.6B | -5.6x | --- |
Spyre Therapeutics Inc | 1.6B | -3.8x | --- |
Praxis Precision Medicines Inc | 1.5B | -7.8x | --- |
Viridian Therapeutics Inc | 1.7B | -5.0x | --- |
ARS Pharmaceuticals Inc | 1.4B | -28.6x | --- |
Syndax Pharmaceuticals Inc | 1.4B | -4.6x | --- |
Company Information
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Contact Information
- Headquarters
- 490 Arsenal Way, Suite 200WATERTOWN, MA, United States 02472
- Phone
- 857-760-0900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Co-Founder
- Paul Berns
- President, Chief Executive Officer, Director
- Henry Gosebruch
- Co-Founder, Chief Operating Officer
- Carol Suh
- Chief Financial Officer
- Joshua Pinto
- Chief Strategy Officer
- Daljit Aurora
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 161.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.77 |
Book Value | $2.95 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
